BridgeBio Pharma, Inc. is an American biotechnology company focused on the development and commercialization of innovative drugs for rare genetic diseases and cancer. Founded in 2015, the company's primary goal is to develop medicines that target the underlying genetic mechanisms causing various rare diseases. BridgeBio leverages advanced scientific technologies to identify genetic causes of diseases and then develops therapeutic options that may alleviate or even eliminate the symptoms of these conditions. The company has a portfolio of therapeutic programs in various stages of clinical trials and collaborates with other biotechnology companies and research institutions to accelerate the development of its products.